HARTMANN raises its earnings forecast for 2024

Heidenheim, December 7, 2023. The HARTMANN GROUP expects moderate organic sales growth and adjusted EBITDA in the range of EUR 200 to 240 million for the 2024 financial year. This represents an increase compared to the last earnings forecast for 2023 of EUR 180 to 210 million.

Transformation Program drives earnings improvement

The consistent implementation of the Transformation Program, which is strengthening the Company's competitive position through product innovations and cost advantages, is expected to make an additional contribution of nearly EUR 50 million to earnings.

Earnings remain burdened by weak markets and high costs

The increase in the earnings forecast comes despite unchanged market challenges, such as reduced market demand and high burdens from additional material costs, as well as increases in personnel costs.

“The improvement in earnings is the result of structural cost reductions and the market launch of new products that offer our customers measurable benefits. This also increases our competitive strength in a market environment that remains difficult,” says Britta Fünfstück, CEO of the HARTMANN GROUP.


The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®) and Infection Management (e. g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” In 2022, the HARTMANN GROUP reported Group sales of EUR 2.3 billion. Founded in 1818, the company sells its products and solutions in 130 countries around the world. For the future, the HARTMANN GROUP is currently implementing its strategic Transformation Program with its high-performance, customeroriented and passionate team.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.